Skip to main content

Castle Biosciences to Participate in Upcoming Investor Conferences

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the following investor conferences next month:

  • Guggenheim Securities Healthcare Innovation Conference on Nov. 11, 2024, at 2:30 p.m. Eastern time.
  • Stephens 26th Annual Investment Conference on Nov. 20, 2024, at 9:00 a.m. Eastern time.

Castle will also be available for one-on-one investor meetings during the UBS Global Healthcare Conference on Nov. 12, 2024. Meetings may be requested exclusively through UBS Investment Bank.

Live audio webcasts of the Company’s presentations will be available by visiting Castle Biosciences’ website at https://ir.castlebiosciences.com/events-presentations/default.aspx. Replays of the webcasts will be available following the conclusion of the broadcasts.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.

DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  248.87
+0.37 (0.15%)
AAPL  263.29
-3.14 (-1.18%)
AMD  275.75
+17.63 (6.83%)
BAC  53.58
-0.74 (-1.37%)
GOOG  333.42
-1.05 (-0.31%)
META  673.78
+2.20 (0.33%)
MSFT  418.58
+7.36 (1.79%)
NVDA  198.18
-0.69 (-0.35%)
ORCL  178.04
+8.23 (4.85%)
TSLA  388.08
-3.87 (-0.99%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.